<DOC>
	<DOCNO>NCT01993888</DOCNO>
	<brief_summary>To evaluate safety hemostatic effectiveness EVARREST® Fibrin Sealant Patch ( EVARREST ) versus standard care treatment ( SoC ) control parenchymal bleed hepatic surgery .</brief_summary>
	<brief_title>The EVARREST® Fibrin Sealant Patch Liver Study</brief_title>
	<detailed_description />
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Fibrin Tissue Adhesive</mesh_term>
	<criteria>Subjects ≥ 18 year age , require elective urgent , open hepatic surgery . Presence appropriate bleeding hepatic parenchymal Target Bleeding Site ( TBS ) identify intraoperatively surgeon Subjects legally authorize representative must willing participate study , provide write informed consent . ( Note : This criterion allow hospital translator use approve Ethics Committees/Institutional Review Boards ) Subjects intraoperative finding identify surgeon may preclude conduct study procedure ; TBS large defect artery vein injure vascular wall require repair maintenance vessel patency would result persistent exposure EVARREST® blood flow pressure heal absorption product ; TBS major arterial bleed require suture mechanical ligation ; Subjects admit trauma surgery ; Subject transplant patient fulminant hepatic failure Subject TBS within actively infected field ; Bleeding site , around , proximity foramen bone , area bony confine ; Subjects know intolerance blood product one component study product unwilling receive blood product ; Subjects know , current alcohol / drug abuser ; Subjects participate another investigational medical device investigational drug trial within 30 day surgery expect participate another medical device investigational drug trial course study ; Female subject pregnant nursing .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Hepatobiliary Surgery</keyword>
</DOC>